Compare Firy Inc. (FIRY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Firy Inc. trades at $12.09 (market cap $199.80M), while Regeneron Pharmaceuticals Inc trades at $747.26 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 381.1× Firy Inc.'s market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Firy Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| FIRY | REGN | |
|---|---|---|
Market Cap | $199.80M | $76.14B |
Volume | 92,993 | 500,239 |
Sector | Technology | Health |
52-Week High | $13.10 | $852.03 |
52-Week Low | $2.28 | $557.73 |
Typical Hold Time | 13 Days | 107 Days |
Enterprise Value | $168.40M | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY trades at $12.18, up 2.78% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $31.0 million but missed EPS expectations with a net loss. Despite a high gross margin of 87.76%, profitability remains challenged with negative net income margin and ROE. Recent developments include a $719 million legal victory and board appointment of Marc Lasry.
The outlook remains cautious due to persistent cash burn and negative earnings, though the legal win provides potential upside. Investment opportunity hinges on successful monetization of legal claims and operational turnaround. Key risks include ongoing cash flow deficits, competitive pressures, and uncertainty around debt collection from Papaya Gaming.
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
